BiotechTube

KCT-0809 ophthalmic solution

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye With Sjögren's Syndrome

Conditions

Dry Eye With Sjögren's Syndrome

Trial Timeline

— → —

NCT ID
NCT02503163

About KCT-0809 ophthalmic solution

KCT-0809 ophthalmic solution is a phase 3 stage product being developed by Kissei Pharmaceutical for Dry Eye With Sjögren's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02503163. Target conditions include Dry Eye With Sjögren's Syndrome.

What happened to similar drugs?

20 of 20 similar drugs in Dry Eye With Sjögren's Syndrome were approved

Approved (20) Terminated (0) Active (0)
✅Tamsulosin OCASAstellas PharmaApproved
✅Mirtazapine TabletsSun PharmaceuticalApproved
✅MecobalaminEisaiApproved
✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
✅Atomoxetine Hydrochloride + placeboEli LillyApproved
✅Eslicarbazepine acetate + Eslicarbazepine AcetateSumitomo PharmaApproved
✅OROS MethylphenidateJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02503176Phase 3Terminated
NCT02503163Phase 3Completed

Competing Products

20 competing products in Dry Eye With Sjögren's Syndrome

See all competitors
ProductCompanyStageHype Score
DFN-15Dr. Reddy's LaboratoriesPhase 2
32
LY3461767 + PlaceboEli LillyPhase 1
29
Glucagon + InsulinAbvance TherapeuticsPhase 1
19
CT-P41 + US-licensed ProliaCelltrionPhase 3
40
LetrozoleChugai PharmaceuticalPhase 2
35
LetrozoleChugai PharmaceuticalPhase 2
35
LetrozoleChugai PharmaceuticalPhase 2
35
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
33
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
DS-5565Daiichi SankyoPhase 3
40
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
PravastatinDaiichi SankyoPre-clinical
26
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
Quizartinib DihydrochlorideDaiichi SankyoPre-clinical
26
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
CS-3150Daiichi SankyoPhase 3
40
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40